Array BioPharma (ARRY) PT Raised to $7 at Jeffeires Ahead of ARRY-797 Data at ESC

August 29, 2016 7:04 AM EDT
Get Alerts ARRY Hot Sheet
Price: $6.42 -2.43%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ARRY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst Eun Yang reiterated a Buy rating and raised its price target on Array BioPharma (NASDAQ: ARRY) to $7.00 (from $6.00) ahead of data at ESC on 8/30/16 potentially showing durable efficacy.

Yang commented, "ARRY-797 for an orphan indication is not a focus for investors. Ahead of add'l data at ESC on 8/30/16 potentially showing durable efficacy, expert notes early 12wk data (~69m increase in 6MWD) is clinically meaningful, warranting Ph3 development. If approved, we see this ultra orphan indication (~2K-3K diagnosed pts in U.S./EU) as potentially meaningful for ARRY (NPV of ~$3/sh for ARRY-797); on 50% probability-adjusted ~$310M peak sales, upping PT to $7."

For an analyst ratings summary and ratings history on Array BioPharma click here. For more ratings news on Array BioPharma click here.

Shares of Array BioPharma closed at $3.24 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Jefferies & Co

Add Your Comment